CLASSIC HODGKIN LYMPHOMA
Clinical trials for CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to beat back advanced hodgkin lymphoma
Disease control OngoingThis phase 3 trial compares two immunotherapy drugs—nivolumab (Opdivo) and brentuximab vedotin (Adcetris)—when added to standard chemotherapy for people aged 12 and older with newly diagnosed stage III or IV classic Hodgkin lymphoma. The goal is to see which combination better de…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New combo therapy aims to beat High-Risk hodgkin lymphoma in kids
Disease control OngoingThis study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can an old drug make immunotherapy work again for hodgkin lymphoma?
Disease control OngoingThis early-phase trial tests whether adding an oral chemotherapy drug (CC-486) to the immunotherapy nivolumab can help patients with Hodgkin lymphoma whose cancer no longer responds to PD-1 blockers. About 33 adults will receive the combination to find the safest dose and see if …
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy combo aims to stop hodgkin lymphoma relapse after transplant
Disease control OngoingThis phase 2 trial is testing whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can prevent Hodgkin lymphoma from coming back after a stem cell transplant. The study includes 62 patients with high-risk Hodgkin lymphoma that had returned or not responded to prior…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cocktail aims to tackle hodgkin lymphoma without prior treatment
Disease control OngoingThis phase 2 trial tests a combination of two targeted drugs (brentuximab vedotin and pembrolizumab) plus standard chemotherapy (doxorubicin and dacarbazine) in 25 people with untreated advanced Hodgkin lymphoma. The goal is to see if this approach is safe and effective. Particip…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Smart scans guide tailored therapy for hodgkin lymphoma patients
Disease control OngoingThis study tests a personalized approach for people with early-stage Hodgkin lymphoma. Doctors use PET scans to decide if standard chemotherapy alone is enough or if adding immunotherapy drugs can improve results. The goal is to boost survival while limiting unnecessary treatment…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug combo offers hope for older hodgkin lymphoma patients who Can't tolerate chemo
Disease control OngoingThis phase 2 trial is testing a combination of two drugs—nivolumab and brentuximab vedotin—in 46 older adults (60+) or those unable to receive standard chemotherapy for untreated Hodgkin lymphoma. The goal is to see if this immunotherapy-based approach can shrink or eliminate tum…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 26, 2026 14:46 UTC